PROCEPT BioRobotics (NASDAQ:PRCT) Sets New 1-Year High at $48.96
PROCEPT BioRobotics (NASDAQ:PRCT) Sets New 1-Year High at $48.96
PROCEPT BioRobotics Co. (NASDAQ:PRCT – Get Rating)'s stock price reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $48.96 and last traded at $48.40, with a volume of 8089 shares traded. The stock had previously closed at $44.87.
納斯達克(股票代碼:PRCT-GET Rating)週四午盤交易中,普羅塞特生物機器人公司的股價創下52周新高。該股盤中一度漲至48.96美元,最新報48.4美元,成交量為8,089股。該股此前收盤報44.87美元。
Analyst Ratings Changes
分析師評級發生變化
PRCT has been the topic of a number of analyst reports. KeyCorp initiated coverage on shares of PROCEPT BioRobotics in a research note on Friday, July 15th. They issued an "overweight" rating and a $47.00 target price on the stock. B. Riley initiated coverage on shares of PROCEPT BioRobotics in a research note on Thursday, June 23rd. They issued a "buy" rating and a $53.00 target price on the stock. Finally, Wells Fargo & Company initiated coverage on shares of PROCEPT BioRobotics in a research note on Friday, September 2nd. They issued an "overweight" rating and a $49.00 target price on the stock. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.50.
PRCT一直是許多分析師報告的主題。KeyCorp在7月15日星期五的一份研究報告中啟動了對Procept BioRobotics股票的報道。他們對該股的評級為“增持”,目標價為47.00美元。B.萊利在6月23日星期四的一份研究報告中對Procept BioRobotics的股票進行了報道。他們對該股的評級為“買入”,目標價為53.00美元。最後,富國銀行在9月2日星期五的一份研究報告中啟動了對Procept BioRobotics股票的報道。他們對該股的評級為“增持”,目標價為49.00美元。一名分析師對該股的評級為持有,七名分析師對該公司的評級為買入。根據MarketBeat的數據,該公司目前的共識評級為“適度買入”,共識目標價為43.50美元。
PROCEPT BioRobotics Stock Performance
Procept BioRobotics股票表現
The stock has a market capitalization of $2.15 billion and a price-to-earnings ratio of -19.35. The company has a quick ratio of 15.27, a current ratio of 16.01 and a debt-to-equity ratio of 0.22. The stock's 50-day simple moving average is $38.53 and its 200 day simple moving average is $35.53.
該股市值21.5億美元,市盈率為-19.35倍。該公司的速動比率為15.27,流動比率為16.01,債務權益比率為0.22。該股的50日簡單移動均線切入位為38.53美元,200日簡單移動均線切入位為35.53美元。
Insider Transactions at PROCEPT BioRobotics
Procept BioRobotics的內幕交易
In other news, Director Thomas M. Krummel sold 20,000 shares of the company's stock in a transaction that occurred on Tuesday, June 21st. The shares were sold at an average price of $35.98, for a total transaction of $719,600.00. Following the transaction, the director now directly owns 82,920 shares in the company, valued at $2,983,461.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 40.80% of the stock is owned by company insiders.
其他新聞方面,董事託馬斯·M·克魯梅爾在6月21日(星期二)的一筆交易中出售了2萬股該公司股票。這些股票的平均價格為35.98美元,總成交額為719,600.00美元。交易完成後,董事現在直接擁有該公司82,920股,價值2,983,461.60美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可在美國證券交易委員會網站上查閲。40.80%的股份由公司內部人士持有。
Hedge Funds Weigh In On PROCEPT BioRobotics
對衝基金參與Procept BioRobotics
A number of large investors have recently modified their holdings of the stock. US Bancorp DE acquired a new position in PROCEPT BioRobotics in the second quarter valued at approximately $37,000. Amalgamated Bank acquired a new position in PROCEPT BioRobotics in the first quarter valued at approximately $39,000. Shell Asset Management Co. acquired a new position in PROCEPT BioRobotics in the second quarter valued at approximately $102,000. MetLife Investment Management LLC acquired a new position in PROCEPT BioRobotics in the first quarter valued at approximately $175,000. Finally, Quantbot Technologies LP acquired a new position in PROCEPT BioRobotics in the second quarter valued at approximately $178,000. 76.23% of the stock is currently owned by institutional investors and hedge funds.
一些大型投資者最近調整了對該股的持有量。US Bancorp DE在第二季度收購了Procept BioRobotics的一個新頭寸,價值約3.7萬美元。合併銀行在第一季度收購了Procept BioRobotics的一個新頭寸,價值約3.9萬美元。殼牌資產管理公司在第二季度收購了Procept BioRobotics的一個新頭寸,價值約為102,000美元。大都會人壽投資管理公司在第一季度收購了Procept BioRobotics的一個新頭寸,價值約為17.5萬美元。最後,Quantbot Technologies LP在第二季度收購了Procept BioRobotics的一個新頭寸,價值約為17.8萬美元。76.23%的股票目前由機構投資者和對衝基金持有。
About PROCEPT BioRobotics
關於Procept BioRobotics
(Get Rating)
(獲取評級)
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
Procept BioRobotics公司是一家外科機器人公司,開發泌尿外科變革性解決方案。該公司開發、製造和銷售AquaBeam機器人系統,這是一種圖像引導的外科機器人系統,用於治療良性前列腺增生症(BPH)的微創泌尿外科手術。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on PROCEPT BioRobotics (PRCT)
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
- These Two Undervalued Stocks Are Ready To Rocket Higher
- GameStop Stock Just Flashed A Buy Signal
- Are Hidden Gems Lurking Among Chemical & Fertilizer Stocks?
- 免費獲取StockNews.com關於Procept BioRobotics(PRCT)的研究報告
- 安相能源有足夠的動力繼續提高動力嗎?
- 獨一無二的氫燃料電池庫存
- 這兩隻被低估的股票已經做好了進一步衝高的準備
- GameStop股票剛剛閃爍了買入信號
- 化工和化肥庫存中是否隱藏着寶藏?
Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Procept BioRobotics日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Procept BioRobotics和相關公司的最新新聞和分析師評級的每日簡要摘要。